@kervio, thanks for your comments on this. I am also really shocked at the primary endpoint being set at a 43% improvement in mortality. I can't see how they would ever realistically have got overwhelming efficacy (e.g. using a sceptical prior) at any interim analysis if this was the goal.
I'm no expert at Bayesian analysis but I had a go at estimating some probability distributions for achieving various levels of mortality reduction for various observed deaths in the treatment arm at the 45% analysis stage (which obviously passed futility). I inferred some mean and standard deviations for both sceptical and enthusiastic priors under various scenarios. I have plotted these below for a particular scenario where 17 deaths were observed in the treatment arm and where there were theoretical deaths of 40.5 (i.e. mortality at 60%) in the control arm. This, I think, would be the 'worst case scenario' / maximum no of deaths that could have been observed at that the 45% stage for continuation of the trial. This also assumes NIH/MSB based futility analysis on an enthusiastic prior and selected 5% as the minimum required probability of achieving the endpoint.
If 17 deaths vs. 40.5 is in fact the worst case, that's still quite a treatment benefit!
- Forums
- ASX - By Stock
- MSB
- Overwhelming efficacy - the stats required
Overwhelming efficacy - the stats required, page-577
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.47 |
Change
-0.045(2.98%) |
Mkt cap ! $1.672B |
Open | High | Low | Value | Volume |
$1.45 | $1.50 | $1.45 | $8.307M | 5.669M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
24 | 151320 | $1.45 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.47 | 55652 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
23 | 150820 | 1.450 |
3 | 79013 | 1.445 |
7 | 113979 | 1.440 |
2 | 54852 | 1.435 |
4 | 159188 | 1.430 |
Price($) | Vol. | No. |
---|---|---|
1.470 | 55652 | 2 |
1.475 | 137352 | 3 |
1.480 | 27852 | 2 |
1.485 | 19000 | 2 |
1.490 | 1000 | 1 |
Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online